In 2020, an AI system called AlphaFold solved a problem that had haunted biologists for 50 years: predicting how proteins fold. The breakthrough was so profound that it was hailed as the biggest achievement in the history of artificial intelligence.
Today, the company built around that breakthrough is about to get much bigger.
Isomorphic Labs, the London‑based AI drug discovery firm spun out of Google’s DeepMind, is in advanced talks to raise more than $2 billion in a new funding round, according to people familiar with the plans and reported by The Economic Times and Bloomberg News. The round would be led by Thrive Capital, the venture firm that also backs OpenAI, with Alphabet also participating.
The money will be used to accelerate its drug design engine and expand its business globally – a clear signal that the era of AI‑discovered medicines is shifting from laboratory curiosity to commercial reality. For India, with its own fast‑growing biotech ecosystem, this moment asks a sharp question: are we building the future of medicine, or just watching it happen?
Quick Facts Box
What Is Isomorphic Labs? The Alphabet-Backed Bet on Curing Disease
Isomorphic Labs was founded in 2021 as a spin‑out from DeepMind, the London‑based AI research lab that Alphabet acquired in 2014. The company is led by Demis Hassabis, the chess prodigy turned neuroscientist turned AI pioneer who also runs DeepMind.
The goal is simple, if audacious: use AI to fundamentally re‑imagine the process of drug discovery. Instead of spending a decade testing millions of molecules in the lab, Isomorphic’s AI models predict how potential drugs will interact with disease‑causing proteins – before a single test tube is touched.
The engine behind this is AlphaFold 3, the latest version of the protein‑folding AI. AlphaFold can now predict not just the shape of individual proteins, but how they interact with other molecules – the key to designing drugs that bind precisely to their targets.
Isomorphic has already signed major partnerships with Eli Lilly, Novartis, and Johnson & Johnson. It is developing its own internal pipeline focused on oncology (cancer) and immunology (autoimmune diseases). In July 2025, the company announced it would begin human clinical trials for an oncology drug created using AlphaFold 3 – a milestone that marks the transition from pure computational research to real‑world medicine.
The $2 Billion Round: Who Is Putting the Money and Why
The reported new funding – over $2 billion – would be Isomorphic’s second external round. Its first, in March 2025, raised $600 million at a valuation that was not publicly disclosed but is widely understood to be in the billions. That round was also led by Thrive Capital.
The fact that Thrive is leading again, with Alphabet joining, signals a high degree of confidence. Thrive is no ordinary venture firm; it was an early backer of OpenAI and has a reputation for placing long‑term, strategic bets on transformative technology.
The timing is also notable. OpenAI itself recently introduced an AI model specifically designed to accelerate drug discovery. A growing number of startups are attempting to apply AI to cut the enormous costs and time of pharmaceutical R&D. Isomorphic’s ability to raise at this scale – even after many high‑profile failures in Silicon Valley’s attempts to break into health and life sciences – suggests that investors believe the AlphaFold approach has moved past the hype phase.
The new capital will be used for two main purposes: advancing Isomorphic’s proprietary drug design engine and expanding its operations globally. While the company has not publicly detailed which regions it will target, the phrase “global expansion” naturally includes Asia and the large, underserved patient populations there.
Read also: Apple Invests ₹100 Crore in India's Green Future: Why This Matters for Your Business
Beyond Isomorphic: Alphabet’s Bigger Bet on AI
Isomorphic is not Alphabet’s only standalone AI bet. The company has a long‑standing strategy of incubating moonshot projects and then spinning them out into independent businesses with their own fundraising and leadership.
Waymo, Alphabet’s autonomous driving unit, raised $16 billion at a $126 billion valuation earlier in 2026. Alphabet is also a major investor in SpaceX and Anthropic, the AI safety startup behind Claude. Antenna, a separate unit focused on wireless technology, raised $1.1 billion last year.
In other words, Isomorphic sits within a carefully constructed portfolio of “other bets” that are now paying off. Together, these investments have boosted Alphabet’s profits in recent years, giving the company the confidence – and the cash – to double down on AI‑driven science. For Isomorphic, this means access not just to capital, but to a vast ecosystem of AI talent, cloud computing infrastructure, and regulatory expertise that few other drug discovery startups can match.
Read also: Crypto Exchange Coinbase Cuts 700 Jobs, Betting Everything on AI
The India Connection: Peptris, ₹70 Crore, and the Fight for Relevance
Now, let us bring the conversation home.
India has a vibrant and rapidly growing biotech sector. The government has designated biotechnology as a national priority, and the Indian biotech market is projected to reach over $300 billion by the end of the decade.
In AI‑driven drug discovery specifically, Indian startups are beginning to make their mark. Peptris Technologies, a Bengaluru‑based pre‑clinical drug discovery company, raised ₹70 crore (approximately $7.7 million) in Series A funding in February 2026, co‑led by IAN Alpha Fund and Speciale Invest.
Read also: Crypto Exchange Coinbase Cuts 700 Jobs, Betting Everything on AI
Peptris has built AI models that generate novel drug molecules and predict critical parameters such as toxicity and efficacy early in the development process – exactly the kind of work that Isomorphic does at a much larger scale. Other Indian players include Bugworks Research, Pandorum Technologies, Elucidata, and DeepCure.ai, each with its own focus, from anti‑infectives to regenerative medicine.
The gap in scale is undeniable. Isomorphic is raising $2 billion; the entire Indian AI drug discovery ecosystem has raised a fraction of that in the same period. But the gap is not unbridgeable. What India lacks in single‑company scale, it makes up for in diversity of approaches, lower operating costs, and a massive pool of pharmaceutical chemists and bioinformaticians.
Moreover, India has a regulatory and clinical advantage. Running clinical trials in India is significantly less expensive than in the US or Europe, and the country has a large, genetically diverse population – an attractive feature for testing drugs that need to work across different ancestries. Global pharmaceutical companies routinely conduct trials in India. There is no reason that AI‑discovered drugs from Indian startups could not follow the same path.
Read also: Marc Lore Says AI Will Enable Anyone to Open a Restaurant in Under a Minute
What Comes Next: From Proteins to Patients
The $2 billion round, if it closes as expected, will accelerate Isomorphic’s timeline. The company is already moving toward human trials for its oncology candidate. Over the next three to five years, we could see the first drugs completely designed by AI enter Phase III trials – the final stage before regulatory approval.
For Indian startups, the window is open but narrow. The pace of AI development means that the technology itself is not the barrier; the barrier is access to capital, to high‑quality biological data, and to the kind of long‑term, patient investors who can afford to wait a decade for a drug to succeed.
The good news is that Indian investors are paying attention. The ₹70 crore raised by Peptris was supported by domestic venture capital firms, not just global funds. The government’s IndiaAI Mission, with its ₹10,372 crore budget, has placed AI at the centre of the country’s technology strategy. If a portion of that funding is directed toward biotech applications, the impact could be significant.
The challenge is that Indian startups must move quickly to form partnerships with major pharmaceutical companies, build defensible intellectual property, and generate the kind of early‑stage data that convinces global investors to write large cheques. Isomorphic had the advantage of being born inside DeepMind, with immediate access to world‑class AI talent and a multi‑year runway. Indian startups do not have that luxury. They must earn their credibility molecule by molecule, test by test.
Read also: MCP vs API: What Every Developer Needs to Know About AI Agent Infrastructure in 2026
The Bottom Line
Isomorphic Labs is about to become one of the richestly funded AI drug discovery companies in the world. Its $2 billion round is a testament to the belief that AlphaFold will transform how medicines are found – and, crucially, that the transformation has already begun.
India cannot afford to sit on the sidelines. The country has the scientists, the software engineers, and the clinical infrastructure to compete. What it needs is a deliberate strategy to channel AI funding into drug discovery, to connect startups with pharmaceutical partners, and to create a regulatory pathway that recognises AI‑generated evidence as part of the approval process.
The chemistry of AI drug discovery is hard. The stakes, however, are simple: who gets to cure the next cancer, and who gets to watch?
Read also: A2A Commerce: How Agent-to-Agent Transactions Will Replace Traditional E-Commerce
FAQ
Q1: What exactly does Isomorphic Labs do?
A: Isomorphic uses Google DeepMind’s AlphaFold AI to predict protein structures and design new drug molecules. Its goal is to shorten the 10‑15-year drug discovery timeline by using computational modelling before any lab tests are done.
Q2: How does this affect India?
A: Indian AI drug discovery startups such as Peptris, Bugworks Research, and Elucidata are working on similar problems but at a much smaller scale. The success of Isomorphic could attract more investment into Indian biotech and encourage global partnerships.
Q3: Is India planning its own version of Isomorphic Labs?
A: India does not yet have a single company at Isomorphic’s scale. However, the IndiaAI Mission and state‑level initiatives are funding AI research. A coordinated effort to create a national AI drug discovery platform has not been announced, but industry groups are advocating for one.
Q4: When will we see an AI‑discovered drug on the market?
A: Isomorphic expects to begin human trials for its oncology drug in 2026. If successful, a drug could reach patients in the early 2030s. AI‑discovered drugs from Indian startups could follow a similar timeline, though none have yet announced plans for human trials.
Q5: What skills should Indian students and professionals focus on to enter this field?
A: Computational biology, bioinformatics, machine learning for protein modelling, cheminformatics, and regulatory science are all in high demand. A background in pharmacy or medicine combined with data science skills is particularly valuable.
Read also: Ask Jeeves Shuts Down After 29 Years: How AI Chatbots Replaced the Original Question Engine
Have you worked in AI‑driven drug discovery or followed the growth of Indian biotech? Which disease would you most like to see an AI‑discovered cure for? Share your thoughts in the comments below.
If you found this article useful, share it with a colleague in healthcare, tech, or science policy – the race to cure disease with AI is already running, and India needs to be part of it.
Tags: Isomorphic Labs, Google DeepMind, AI Drug Discovery, Thrive Capital, AlphaFold, Indian Biotech, HealthTech
Have a question about AI or the latest tech trends? We’d love to hear your thoughts!
Please stay on topic and keep it helpful. Note: All comments are moderated to keep our community spam-free.